APRE net incomeQ3 2026-$4.81M
APRE net income was -$4.81M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$2.97M a year earlier. For the full fiscal 2025 it was -$12.60M, compared with -$12.96M in fiscal 2024.
Aprea Therapeutics Inc. (APRE) financials
For the twelve months ended Sep 30, 2026, Aprea Therapeutics Inc. reported -$14.14M of net income.
- Net income, TTM
- -$14.14M
- EPS, diluted, TTM
- -$0.65
- Cash
- $37.85M
- Market cap
- $7.1M
FY2017FY2025
FY2018FY2024
APRE revenue and earnings growth
APRE EPSQ3 2026-$0.09
APRE diluted EPS was -$0.09 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$1.93, compared with -$2.35 in fiscal 2024.
APRE free cash flowQ3 2026-$3.73M
APRE free cash flow was -$3.73M in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2024 it was -$13.57M, compared with -$12.27M in fiscal 2023.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Research and development | $7.04M | $9.36M | $7.63M | $16.40M | $23.90M | $37.88M | $20.95M | $14.19M | $13.39M |
| Selling, general and admin | $6.48M | $6.46M | $8.43M | $20.97M | $13.55M | $14.93M | $8.59M | $2.29M | $2.46M |
| Operating income | -$13.23M | -$14.32M | -$15.47M | -$113.39M | -$37.45M | - | - | - | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.60M | -$12.96M | -$14.29M | -$112.66M | -$37.13M | -$53.48M | -$28.06M | -$15.53M | -$15.19M |
| EPS, basic | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$93.40 | -$269.00 | -$263.40 |
| EPS, diluted | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$93.40 | -$269.00 | -$263.40 |
| Diluted shares | 6.5M | 5.5M | 3.6M | 1.7M | 1.1M | 1.1M | 300,124.3 | 57,718.4 | 57,653.45 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.60M | $22.89M | $21.65M | $28.79M | $53.08M | $89.02M | $130.09M | $65.68M | $24.40M |
| Current assets | $15.56M | $23.58M | $22.52M | $30.15M | $56.58M | $92.42M | $133.04M | $66.00M | - |
| Total assets | $15.93M | $23.98M | $22.65M | $30.16M | $56.82M | $92.81M | $133.61M | $66.02M | - |
| Current liabilities | $2.76M | $3.36M | $4.39M | $3.20M | $7.32M | $15.33M | $9.06M | $4.87M | - |
| Total liabilities | - | - | - | $3.20M | $7.32M | $15.41M | $9.36M | $4.87M | - |
| Shareholders' equity | $12.44M | $19.31M | $16.95M | $25.64M | $49.51M | $77.40M | $124.24M | -$51.44M | -$35.77M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.89M | -$13.56M | -$12.18M | -$25.01M | -$37.69M | -$41.80M | -$26.71M | -$15.25M | -$14.00M |
| Capital expenditures | - | $15.5K | $93.1K | - | - | $25.7K | $30.9K | $3.7K | - |
| Free cash flow | - | -$13.57M | -$12.27M | - | - | -$41.83M | -$26.74M | -$15.25M | - |
| Investing cash flow | - | -$15.5K | -$93.1K | - | - | -$25.7K | -$30.9K | -$3.7K | - |
| Financing cash flow | $4.64M | $14.82M | $5.14M | $683.0K | $1.75M | $150.9K | $92.58M | $56.37M | $23.34M |
| Depreciation and amortization | $21.7K | $22.3K | $7.1K | $4.4K | $12.8K | $28.8K | $11.1K | $8.3K | $7.9K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -101.3% | -67.1% | -84.3% | -439.3% | -75.0% | -69.1% | -22.6% | - | - |
| Return on assets | -79.1% | -54.0% | -63.1% | -373.6% | -65.3% | -57.6% | -21.0% | -23.5% | - |
| Current ratio | 5.63 | 7.01 | 5.14 | 9.42 | 7.73 | 6.03 | 14.68 | 13.56 | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.34M | $2.46M | $1.61M | $1.01M | $1.64M | $1.91M | $2.48M | $2.36M | $2.85M | $2.56M | $1.60M | $2.05M |
| Selling, general and admin | $1.83M | $1.57M | $1.82M | $1.64M | $1.48M | $1.59M | $1.76M | $1.07M | $1.61M | $1.85M | $1.93M | $1.64M |
| Operating income | -$5.17M | -$4.03M | -$3.43M | -$2.64M | -$3.12M | -$3.39M | -$4.09M | -$3.23M | -$4.10M | -$3.85M | -$3.15M | -$3.67M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$4.81M | -$3.59M | -$3.29M | -$2.46M | -$2.97M | -$3.24M | -$3.93M | -$2.89M | -$3.78M | -$3.47M | -$2.81M | -$3.44M |
| EPS, basic | -$0.09 | -$0.07 | -$0.22 | -$0.27 | -$0.47 | -$0.53 | -$0.66 | - | -$0.64 | -$0.58 | -$0.67 | -$0.88 |
| EPS, diluted | -$0.09 | -$0.07 | -$0.22 | -$0.27 | -$0.47 | -$0.53 | -$0.66 | - | -$0.64 | -$0.58 | -$0.67 | -$0.88 |
| Diluted shares | 53.7M | 53.5M | 14.7M | - | 6.4M | 6.1M | 6.0M | - | 5.9M | 5.9M | 4.2M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $37.85M | $41.23M | $46.47M | $14.60M | $13.72M | $16.53M | $19.28M | $22.89M | $26.25M | $28.69M | $32.37M | $21.65M |
| Current assets | $38.44M | $41.91M | $47.25M | $15.56M | $13.94M | $16.93M | $19.83M | $23.58M | $26.48M | $29.56M | $33.07M | $22.52M |
| Total assets | $38.81M | $42.29M | $47.61M | $15.93M | $14.32M | $17.31M | $20.22M | $23.98M | $26.89M | $29.96M | $33.20M | $22.65M |
| Current liabilities | $3.97M | $3.09M | $5.30M | $2.76M | $2.68M | $3.17M | $3.36M | $3.36M | $3.64M | $3.09M | $2.97M | $4.39M |
| Shareholders' equity | $34.11M | $38.47M | $41.59M | $12.44M | $10.91M | $13.41M | $15.55M | $19.31M | $21.95M | $25.56M | $28.92M | $16.95M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.73M | -$3.28M | -$2.76M | -$2.96M | -$3.17M | -$3.13M | -$3.63M | -$3.51M | -$2.47M | -$3.64M | -$3.94M | -$3.74M |
| Capital expenditures | $1 | - | - | - | - | - | - | $0 | $0 | $7.5K | $8.0K | $7.2K |
| Free cash flow | -$3.73M | - | - | - | - | - | - | -$3.51M | -$2.47M | -$3.65M | -$3.94M | -$3.75M |
| Investing cash flow | -$1 | - | - | - | - | - | - | $0 | $0 | -$7.5K | -$8.0K | -$7.2K |
| Financing cash flow | $342.0K | -$1.94M | $34.62M | $3.84M | $357.9K | $384.9K | $55.8K | $134.4K | -$1.2K | -$21.1K | $14.71M | $0 |
| Depreciation and amortization | $5.9K | $5.7K | $5.4K | $5.4K | $5.4K | $5.4K | $5.4K | $5.4K | $5.4K | $5.3K | $6.2K | $5.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 9.67 | 13.55 | 8.92 | 5.63 | 5.20 | 5.34 | 5.90 | 7.01 | 7.28 | 9.55 | 11.15 | 5.14 |
Source: XBRL data Aprea Therapeutics Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Mar 30, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
APRE peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| APRE | - | - | -$14.14M | - | $7.1M |
| RIGL | $288.21M | +2.2% | $307.19M | 106.6% | $791.8M |
| KURA | $77.22M | - | -$296.77M | -384.3% | $673.4M |
| GERN | - | - | -$47.83M | - | $644.1M |
| RFL | $874.0K | -4.7% | -$29.64M | -3390.7% | $56.4M |
| KPTI | $146.62M | +6.8% | -$224.74M | -153.3% | $996,170 |
APRE FAQ
5 questionsIs APRE profitable?
No. Aprea Therapeutics Inc. reported a net loss of $14.14M for the twelve months ended Sep 30, 2026.How much cash and debt does APRE have?
Aprea Therapeutics Inc. reported $37.85M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is APRE earnings per share?
Diluted earnings per share were -$0.65 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did APRE last report financial results?
The latest statements here come from Aprea Therapeutics Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.Where does this APRE financial data come from?
Quantisnow builds these statements from the structured XBRL data Aprea Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.